Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida. more
Time Frame | ZVRA | Sector | S&P500 |
---|---|---|---|
1-Week Return | -1.93% | -2.12% | 0.77% |
1-Month Return | 3.86% | -2.54% | 2.65% |
3-Month Return | 25% | -6.28% | 12.3% |
6-Month Return | 93.86% | -1.36% | 13.48% |
1-Year Return | 84.85% | 9.29% | 33.47% |
3-Year Return | 12.55% | 10.05% | 32.22% |
5-Year Return | 52.91% | 43.69% | 92.85% |
10-Year Return | -94.89% | 103.1% | 194.31% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 12.84M | 13.29M | 28.65M | 10.46M | 27.46M | [{"date":"2019-12-31","value":44.81,"profit":true},{"date":"2020-12-31","value":46.38,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":36.5,"profit":true},{"date":"2023-12-31","value":95.85,"profit":true}] |
Cost of Revenue | 2.94M | 1.30M | 2.06M | 343.00K | 2.94M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":44.31,"profit":true},{"date":"2021-12-31","value":69.92,"profit":true},{"date":"2022-12-31","value":11.65,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 9.89M | 11.98M | 26.59M | 10.12M | 24.52M | [{"date":"2019-12-31","value":37.21,"profit":true},{"date":"2020-12-31","value":45.06,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":38.04,"profit":true},{"date":"2023-12-31","value":92.2,"profit":true}] |
Gross Margin | 77.06% | 90.18% | 92.81% | 96.72% | 89.28% | [{"date":"2019-12-31","value":79.68,"profit":true},{"date":"2020-12-31","value":93.24,"profit":true},{"date":"2021-12-31","value":95.96,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":92.3,"profit":true}] |
Operating Expenses | 30.23M | 16.76M | 18.86M | 34.96M | 74.12M | [{"date":"2019-12-31","value":40.79,"profit":true},{"date":"2020-12-31","value":22.62,"profit":true},{"date":"2021-12-31","value":25.45,"profit":true},{"date":"2022-12-31","value":47.16,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (20.34M) | (4.78M) | 7.73M | (24.84M) | (49.60M) | [{"date":"2019-12-31","value":-263.13,"profit":false},{"date":"2020-12-31","value":-61.86,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-321.41,"profit":false},{"date":"2023-12-31","value":-641.79,"profit":false}] |
Total Non-Operating Income/Expense | (10.41M) | (14.19M) | (16.38M) | (1.54M) | 7.25M | [{"date":"2019-12-31","value":-143.63,"profit":false},{"date":"2020-12-31","value":-195.7,"profit":false},{"date":"2021-12-31","value":-225.93,"profit":false},{"date":"2022-12-31","value":-21.22,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (24.54M) | (12.79M) | (8.52M) | (42.33M) | (46.05M) | [{"date":"2019-12-31","value":-2454400000,"profit":false},{"date":"2020-12-31","value":-1279400000,"profit":false},{"date":"2021-12-31","value":-852100000,"profit":false},{"date":"2022-12-31","value":-4232900000,"profit":false},{"date":"2023-12-31","value":-4604900000,"profit":false}] |
Income Taxes | (22.00K) | (34.00K) | 34.00K | (786.00K) | - | [{"date":"2019-12-31","value":-64.71,"profit":false},{"date":"2020-12-31","value":-100,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-2311.76,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (24.52M) | (12.76M) | (8.55M) | (41.54M) | - | [{"date":"2019-12-31","value":-2452200000,"profit":false},{"date":"2020-12-31","value":-1276000000,"profit":false},{"date":"2021-12-31","value":-855500000,"profit":false},{"date":"2022-12-31","value":-4154300000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (24.52M) | (12.76M) | (8.55M) | (41.54M) | (39.92M) | [{"date":"2019-12-31","value":-2452200000,"profit":false},{"date":"2020-12-31","value":-1276000000,"profit":false},{"date":"2021-12-31","value":-855500000,"profit":false},{"date":"2022-12-31","value":-4154300000,"profit":false},{"date":"2023-12-31","value":-3991700000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (24.52M) | (12.76M) | (8.55M) | (41.54M) | (46.05M) | [{"date":"2019-12-31","value":-2452200000,"profit":false},{"date":"2020-12-31","value":-1276000000,"profit":false},{"date":"2021-12-31","value":-855500000,"profit":false},{"date":"2022-12-31","value":-4154300000,"profit":false},{"date":"2023-12-31","value":-4604900000,"profit":false}] |
EPS (Diluted) | (11.84) | (3.31) | (0.46) | (0.69) | (1.29) | [{"date":"2019-12-31","value":-1184,"profit":false},{"date":"2020-12-31","value":-331,"profit":false},{"date":"2021-12-31","value":-46,"profit":false},{"date":"2022-12-31","value":-69,"profit":false},{"date":"2023-12-31","value":-129,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ZVRA | |
---|---|
Cash Ratio | 1.57 |
Current Ratio | 2.88 |
Quick Ratio | 2.63 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ZVRA | |
---|---|
ROA (LTM) | -32.81% |
ROE (LTM) | -130.67% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ZVRA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.64 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.36 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ZVRA | |
---|---|
Trailing PE | NM |
Forward PE | 192.31 |
P/S (TTM) | 20.01 |
P/B | 7.02 |
Price/FCF | NM |
EV/R | 18.81 |
EV/Ebitda | NM |
PEG | 10.67 |
Zevra Therapeutics Inc. (ZVRA) share price today is $9.15
Yes, Indians can buy shares of Zevra Therapeutics Inc. (ZVRA) on Vested. To buy Zevra Therapeutics Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ZVRA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Zevra Therapeutics Inc. (ZVRA) via the Vested app. You can start investing in Zevra Therapeutics Inc. (ZVRA) with a minimum investment of $1.
You can invest in shares of Zevra Therapeutics Inc. (ZVRA) via Vested in three simple steps:
The 52-week high price of Zevra Therapeutics Inc. (ZVRA) is $9.76. The 52-week low price of Zevra Therapeutics Inc. (ZVRA) is $4.2.
The price-to-earnings (P/E) ratio of Zevra Therapeutics Inc. (ZVRA) is
The price-to-book (P/B) ratio of Zevra Therapeutics Inc. (ZVRA) is 7.02
The dividend yield of Zevra Therapeutics Inc. (ZVRA) is 0.00%
The market capitalization of Zevra Therapeutics Inc. (ZVRA) is $489.99M
The stock symbol (or ticker) of Zevra Therapeutics Inc. is ZVRA